Status:
COMPLETED
Gene Expression Profiles in Multiple Sclerosis (MS)
Lead Sponsor:
University of California, Davis
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-70 years
Brief Summary
The purpose of this study is to test differences in RNA levels between Multiple Sclerosis (MS) patients and normal subjects. RNA provides a "message" from genes altered in diseases. We will also test ...
Detailed Description
This is an investigator-initiated, pilot study of gene expression (RNA) in the blood of patients with multiple sclerosis (MS). The study will enroll patients from the UC Davis Multiple Sclerosis clini...
Eligibility Criteria
Inclusion
- males and females
- any race
- Between the ages of 18 and 70 years
- Diagnosed with a clinically isolated syndrome or the diagnosis of multiple sclerosis using the widely established Macdonald criteria. A 'clinically isolated syndrome' refers to an isolated attack of optic neuritis, transverse myelitis, or brain demyelination. Relapsing-remitting MS is characterized by acute relapses that are followed by some degree of recovery without worsening of disability between relapses. Chronic progressive MS is defined as sustained progression of physical disability, occurring separately from relapses, in patients with MS.
- Control subjects will be male or female, between the ages 18 to 70 years, of any race, with no symptoms of MS.
Exclusion
- Children are excluded from the study because MS is generally a disease of young adult onset and is rare in children.
- Evidence of infection or communicable disease, cancer or other known systemic disease, anti-coagulation, known bleeding disorder, illicit drug abuse, or change in medications in the last 30 days (including treatment with steroids).
- Patients receiving any other immune modulating medications (steroids, cyclophosphamide, mitoxantrone, methotrexate, mycophenolate mofetil, azathioprine, IVIG or rituximab) in the prior thirty days will be excluded from the study
Key Trial Info
Start Date :
March 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 5 2017
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00704834
Start Date
March 1 2006
End Date
July 5 2017
Last Update
February 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Davis
Sacramento, California, United States, 95817